Navigation Links
Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
Date:9/10/2013

ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the First Global Life Sciences Conference to be held on September 16-17, 2013 in Warsaw, Poland. Mr. Riley is scheduled to present at 11:15 a.m. (Central European Summer Time)/5:15 a.m. (Eastern Time) on Monday, September 16, 2013 at the Warsaw Stock Exchange.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO )

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://www.wdmcapital.com/en/strony/lsc/live_webcast.html. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with conference attendees. To arrange a one-on-one meeting with Synthetic Biologics, please contact Wojciech Grzegorczyk at wojciech.grzegorczyk@wdmsa.pl or by phone +48 784 094 599.

WDM Capital, a prominent small cap investment bank in Central and Eastern Europe, is organizing the conference in partnership with the Warsaw Stock Exchange and Deloitte. For more information visit: http://lscwarsaw.com.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Synthetic Biologics Reports Second Quarter 2012 Financial Results
4. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
5. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
6. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
7. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
8. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
9. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
10. Synthetic Biologics to Present at the 25th Annual ROTH Conference
11. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016   Change Healthcare , a ... solutions and technology-enabled services designed to enable ... a strategic channel partnership with SourceMed, the ... and revenue cycle management services that empower ... clinics to optimize revenue, operational efficiency and ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
Breaking Medicine Technology:
(Date:5/27/2016)... Newark, NJ (PRWEB) , ... May 27, 2016 , ... ... been named as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The ... to their workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... An ... returns for a third time to shed lights on the variety of topics detailing ... inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in a ...
(Date:5/27/2016)... , ... May 27, 2016 , ... This campaign aims ... stroke, which we as a society can control and change. , As nearly 795,000 ... every 40 seconds within the United States. Plus, with an estimated 129,000 of these ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
Breaking Medicine News(10 mins):